Full text is available at the source.
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
Once-weekly semaglutide use in type 2 diabetes patients new to GLP-1 receptor agonists in North Macedonia: Real-world data
AI simplified
Abstract
In a study of 314 patients, a statistically significant mean change in HbA1c of -2.2 % points was observed after 30 weeks of treatment with once weekly subcutaneous semaglutide.
- Patients had a mean age of 55.5 years and an average baseline HbA1c of 9.0 %.
- At the end of the study, 62.1 % of patients achieved an HbA1c level below 7 %.
- Patients experienced an estimated mean weight loss of -9.0 kg.
- Fasting plasma glucose decreased by an average of -4.1 mmol/L.
- A weight reduction of ≥ 3 % and ≥ 5 % was noted in 88.3 % and 73.3 % of patients, respectively.
- No new safety concerns were identified during the study.
AI simplified